Financial Performance - Satellogic's total revenue for the year ended December 31, 2025, was $17.707 million, a 37% increase from $12.870 million in 2024[74]. - As of December 31, 2025, the company has an accumulated deficit of $404.9 million and net cash used in operating activities of $26.9 million for the year[173]. - The company had cash and cash equivalents of $94.4 million as of December 31, 2025, indicating ongoing financial challenges until sufficient customer onboarding occurs[173]. - In 2025, three customers accounted for over 10% of total revenue, highlighting dependency on a small number of clients[178]. - The company does not expect to declare any dividends in the foreseeable future, indicating a focus on reinvestment[176]. Market Opportunities - The Earth Observation sector is projected to contribute $3.8 trillion to global GDP between 2023 and 2030, driven by productivity increases across key industries[79]. - The cumulative global manufacturing revenue for Earth Observation satellites is estimated to reach approximately $101 billion by 2034, indicating a significant market opportunity[83]. - The company expects the high-resolution EO market to reflect the majority of its revenue over the next two to three years, providing operational cash flow for its constellation[96]. Product and Technology Development - The Data & Analytics business is expected to remain the most predictable revenue stream, driving future growth alongside Space Systems[69]. - The Aleph Observer product enables ongoing monitoring of hundreds of sites daily, significantly enhancing operational efficiency and reducing costs for customers[70]. - The Merlin AI-First constellation is projected to launch its first satellite in Q4 2026 and become fully operational in the first half of 2027, expanding monitoring capacity to potentially millions of sites daily[71]. - The company introduced the NextGen platform in October 2025, featuring 30 cm resolution and AI-enabled analytics, expected to be operational by 2028[95]. - The company aims to leverage AI-powered analytics through its Aleph Observer product and the upcoming Merlin constellation to deliver proactive intelligence[91]. Strategic Partnerships and Contracts - A multi-year contract valued at $30 million was awarded in April 2025 for near-daily multiband optical imagery and ultra-low latency analytics, with revenue expected in 2027[120]. - A five-year agreement with a technology company requires a minimum purchase of $4 million annually, recognized as $4.4 million in revenue during 2025[114][116]. - The company is pursuing strategic acquisitions and partnerships to enhance its go-to-market strategy, including agreements with Vantor and Suhora Technologies[91]. Operational Challenges - The company is transitioning to commercial production and sales, facing challenges in forecasting future results and customer retention[173]. - The sales cycle for the company's offerings is long and unpredictable, with significant time and expense invested in evaluating potential customers' needs[179]. - The company faces risks related to pricing structures, which may require adjustments over time to avoid missed revenue opportunities or losing bids[181]. - The ability to scale satellite production is critical, with potential delays or increased costs impacting expected revenue and profitability[182][185]. - The company relies on third-party vendors for satellite components and launch services, with any delays potentially having a material adverse impact on operations[187][188]. Regulatory and Compliance Issues - The company is subject to NOAA's oversight after obtaining an operator's license in November 2023, as it shifts operational control of its satellite constellation to U.S. personnel[143]. - Compliance with U.S. export control laws is critical, as violations could result in penalties and impact the ability to secure government contracts[251]. - The company’s growth strategy includes obtaining U.S. governmental agency customers, particularly in defense and intelligence, which is subject to U.S. regulations[258]. - Failure to maintain required cybersecurity controls for CMMC certification could result in ineligibility for certain DoD contracts, adversely affecting business operations[259]. Risks and Uncertainties - The company faces competition from various sectors, including commercial satellite imagery, state-owned providers, and free sources, which may limit market share growth[202]. - The increasing number of satellites in low Earth orbit raises the risk of collisions, which could materially affect the company's ability to access sufficient orbital slots for business growth[227]. - Prolonged unfavorable weather conditions may negatively impact satellite operations, affecting data collection and communication quality[243]. - The occurrence of anomalies in satellites can significantly degrade performance, impacting the ability to collect imagery and market products successfully, which could materially affect revenues[226]. - The company is vulnerable to natural disasters and geopolitical events that could disrupt operations and satellite launch schedules, adversely affecting operating results[240].

Revenue and Business Model - The ARK franchise contributed 89.4% of the company's net revenue for the year ended December 31, 2025, with the five best-selling franchises accounting for 96.6% of net revenue[92]. - 95.1% of the company's revenues for the year ended December 31, 2025, were generated through third-party platforms such as Xbox Live, PlayStation Network, and the Apple App Store[109]. - 95.1% of the company's net revenue for the year ended December 31, 2025, was derived from publishing video games on third-party platforms[125]. - The company recognizes a majority of revenues from video games on a deferred basis, which could significantly affect reported financial results as the business evolves[193]. Competition and Market Risks - The company faces intense competition in the interactive entertainment software industry, with a small number of hit titles accounting for a large portion of total revenue[92]. - The interactive entertainment software industry is highly competitive, with major competitors like Sony, Microsoft, and Activision Blizzard, which may impact the company's ability to develop hit titles[120]. - The company faces significant risks from natural disasters, cyber-attacks, and geopolitical tensions, which could disrupt operations and adversely affect future operating results[105]. - The company is vulnerable to service disruptions from DDoS attacks and other cybersecurity threats, which could negatively impact its online games[90]. Growth and Investment - The company has experienced rapid growth and plans to continue investing in growth, but failure to manage this growth effectively could adversely affect its business and financial condition[90]. - The company is experiencing significant growth in complexity and scope, including new business models like eSports and influencer platforms, but forecasting success is inherently uncertain[118]. - The company plans to continue investing in its growth, although sustaining current growth rates is uncertain[137]. - The company is expanding into new products and services, which involves risks such as increased capital requirements and potential new competition[141]. Management and Governance - The management team has limited experience managing a public company, which could pose risks to the company's operations[88]. - Mr. Shi controls the majority of voting power, affecting board composition and business direction[202]. - The concentration of Mr. Shi's ownership may discourage tender offers, impacting stockholder premiums[203]. - The company is classified as a "controlled company," which allows it to rely on exemptions from certain corporate governance requirements, potentially limiting stockholder protections[198]. Financial Condition and Compliance - The company has significant debt obligations due within one year, including a revolving loan balance of $5.0 million with a repayment date extended to March 31, 2030[195]. - The effective tax rate was (64.6)% for the year ended December 31, 2025, and 25.7% for the year ended December 31, 2024, indicating potential volatility in future profitability due to tax law changes[191]. - The company has met the minimum debt service coverage ratio required by its debt covenants for the trailing twelve months ended December 31, 2025[196]. - The company has identified a material weakness in internal control over financial reporting related to the fair value determination of warrants, which has been remediated, but future weaknesses may still arise[227]. Legal and Regulatory Risks - The company is subject to evolving regulations regarding AI, which may impose significant compliance obligations and affect its operations[150]. - Changes in data privacy and security laws, such as the California Consumer Privacy Act (CCPA), could increase operational costs and regulatory scrutiny, impacting business practices and product offerings[173]. - The General Data Protection Regulation (GDPR) imposes strict compliance obligations, with potential fines of up to €20 million or 4% of total worldwide annual turnover for non-compliance, affecting operational costs and risk exposure[174]. - Proposed federal legislation in the U.S. could limit the retail market for the company's products, adversely affecting financial results[177]. Technology and Cybersecurity - The company utilizes artificial intelligence, which could expose it to liability or adversely affect its business[90]. - The integration of artificial intelligence (AI) is expected to drive innovation and operational efficiencies, but also poses risks including potential biases and cybersecurity threats[148]. - The company is critically dependent on the integrity and security of its information technology systems, with potential cybersecurity breaches posing risks to sales, subscriptions, and reputational damage[171]. - The company is vulnerable to large-scale DDoS attacks, which have previously caused server outages and disrupted player access to games[116]. Stock and Capital Management - The company authorized a share repurchase program of up to $5 million, with approximately $1.3 million remaining for future repurchases as of December 31, 2025[214]. - The company does not anticipate paying cash dividends in the foreseeable future, making capital appreciation the sole source of gain[218]. - The company plans to rely on the Equity Line Investor for funding, with a potential sale of $5.0 million in Class A common stock and an additional $5.5 million in convertible notes, but may still require further capital[242]. - The issuance of Class A common stock to holders of the 2025 Convertible Notes could lead to significant dilution for existing shareholders, with up to 5,414,991 shares registered for resale[245]. User Engagement and Retention - Consumer preferences for games are cyclical and difficult to predict, which could lead to fluctuations in revenue and profitability[93]. - The company must continually attract and retain users to maintain its financial performance, particularly in the new short film drama business[142]. - User metrics, including active and paying users, are subject to measurement challenges, which could lead to inaccuracies affecting revenue and financial results[140]. - The company may adjust in-app pricing, which could negatively impact user retention and business growth[145].

Revenue and Growth - Total revenue increased by $132.4 million, or 19.7%, to $805.7 million for 2025 compared to $673.3 million for 2024, primarily due to the acquisition of Safflower Holdings Corp.[168] - Owned restaurant net revenue increased to $791,762,000 for the year ended December 28, 2025, up from $658,915,000 in 2024, representing a growth of approximately 20.1%[210] - Total revenues rose to $805,722,000 in 2025, compared to $673,344,000 in 2024, marking an increase of about 19.6%[210] - Owned restaurant net revenue rose to $791.8 million in 2025, up from $658.9 million in 2024, primarily driven by the acquisition of Benihana and RA Sushi restaurants[222] - Total revenues for the year ended December 28, 2025, were $814.2 million, reflecting an increase of $132.9 million, or 20.2%, from $658.9 million in 2024[222] Restaurant Performance - Same store sales for STK restaurants decreased by 3.7% in 2025 compared to 2024, with a notable decline in managed restaurants of 4.6%[169][183] - The average comparable STK restaurant revenues were $14.2 million for 2025, down from $15.5 million in 2024, indicating a decline in customer traffic[188] - Comparable restaurant sales decreased by 3.7% in 2025 compared to 2024, attributed to the current economic and macro environment[222] Profitability and Losses - Net loss attributable to The ONE Group Hospitality, Inc. was $92.2 million in 2025, a significant decline from a net income of $17.1 million in 2024, primarily due to a non-cash tax valuation allowance[172] - Net loss attributable to The ONE Group Hospitality, Inc. increased to $92.2 million for the year ended December 28, 2025, compared to a loss of $17.1 million for the year ended December 31, 2024[213] - EBITDA and Adjusted EBITDA are key metrics used to evaluate operating performance, with Adjusted EBITDA being a critical measure for debt compliance calculations[206][207] Expenses and Cost Management - Owned restaurant cost of sales as a percentage of net revenues decreased to 20.7% in 2025 from 21.1% in 2024, indicating improved cost management[212] - Owned restaurant operating expenses increased to $503,070,000 in 2025, up from $413,587,000 in 2024, reflecting a rise of approximately 21.7%[210] - General and administrative expenses were $52,540,000 in 2025, compared to $44,234,000 in 2024, showing an increase of about 18.8%[210] - Transition and integration expenses related to the Benihana acquisition were $11,202,000 in 2025, down from $13,681,000 in 2024[210] - Owned restaurant operating expenses increased by $89.5 million, or 21.6%, to $503.1 million for 2025, primarily due to the acquired Benihana and RA Sushi restaurants[225] - General and administrative costs rose to $52.5 million in 2025, an increase of $8.3 million, or 18.8%, from $44.2 million in 2024[226] Future Plans and Developments - The company plans to open six to ten new venues in 2026, with several STK and Benihana restaurants currently under construction[161][177] - The company expects to grow the STK brand to 200 restaurants globally, with plans to open three to five STKs annually[173] - In December 2025, the company secured development rights for ten new restaurants in the Greater San Francisco Bay Area, marking its largest asset-light development agreement[178] - The company plans to convert up to nine Company-owned Grill restaurants to Benihana or STK formats, with five conversions expected by the end of 2026, requiring about $1.0 million in capital investment each[249] Cash Flow and Capital Expenditures - Net cash provided by operating activities was $30.3 million for 2025, down from $44.1 million in 2024, primarily due to the timing of collections on credit card receivables[255] - Capital expenditures in 2025 totaled $57.6 million, with $30.0 million allocated for new restaurant constructions and $7.4 million for remodels[258] - Net cash used in investing activities for 2025 was $57.6 million, significantly lower than $441.4 million in 2024, which included $369.8 million for the Benihana acquisition[259] Debt and Financial Position - As of December 28, 2025, the company had cash and cash equivalents of $4.0 million and long-term debt of $354.2 million[243] - The availability on the revolving credit facility was $27.2 million as of December 28, 2025, subject to certain conditions[243] - The company had $351.3 million of borrowings subject to variable interest rates as of December 28, 2025, with a hypothetical 1% rise in interest rates increasing interest expense by $3.5 million annually[286] Impairment and Valuation - As of December 28, 2025, the company had a valuation allowance of $75.1 million against deferred tax assets[266] - For the year ended December 28, 2025, the company recorded non-cash impairment charges of $6.4 million on property and equipment and $0.7 million in lease termination and exit expenses[270] - The company recorded non-cash impairment charges of $4.2 million on the Kona Grill tradename for the year ended December 28, 2025[277] - The company has not recorded any impairment charges related to goodwill in 2025 or 2024[277] Miscellaneous - The company continues to evaluate potential acquisition opportunities to leverage system-wide operating efficiencies as its footprint increases[181] - The company does not currently use financial instruments to hedge foreign currency exchange rate changes, which may impact international operating results[288]

Clinical Development and Trials - Genelux is focused on developing oncolytic viral immunotherapies, with its lead product candidate, Olvi-Vec, currently in late-stage clinical trials[16]. - Olvi-Vec is being evaluated in three clinical trials: a Phase 3 trial for platinum-resistant ovarian cancer, a Phase 2 trial for recurrent non-small cell lung cancer (NSCLC), and a Phase 1b/2 trial for recurrent small cell lung cancer (SCLC)[18][21]. - The Phase 3 OnPrime/GOG-3076 trial aims to enroll patients with platinum-resistant/refractory ovarian cancer, with topline results expected in the second half of 2026[36][38]. - The clinical trials have shown that Olvi-Vec is well tolerated, with no maximum tolerated dose reached and no significant issues with virus shedding[31][42]. - Olvi-Vec has demonstrated the ability to selectively kill tumor cells and enhance the effectiveness of chemotherapy in combination therapy settings[31]. - In the Phase 2 trial, patients receiving Olvi-Vec-primed immunochemotherapy showed an overall response rate (ORR) of 54%, with 19% complete responses (CRs) and 35% partial responses (PRs)[45]. - Median progression-free survival (PFS) for heavily pretreated patients was 11.0 months, compared to historical expectations of less than 4 months[45]. - The median overall survival (OS) for patients was 15.7 months, exceeding the historical median of less than 12 months[45]. - The trial results supported moving into a Phase 3 trial after exceeding the pre-defined threshold of 43% for objective responders[46]. - In the ongoing Phase 2 VIRO-25 trial for recurrent non-small cell lung cancer (NSCLC), initial results showed a disease control response (DCR) of 60% among evaluable patients[55]. - The Phase 1b/2 clinical trial for small cell lung cancer (SCLC) reported an overall response rate (ORR) of 33%, with a DCR of 67%[61]. - The company is conducting a Phase 2 clinical trial of Olvi-Vec for the treatment of recurrent non-small cell lung cancer (NSCLC) and has not yet initiated a registrational trial[86]. - The Phase 3 registration trial of Olvi-Vec in PRROC initiated enrollment in Q3 2022, with topline results anticipated in the second half of 2026[183]. - Enrollment for the Phase 3 registration trial of Olvi-Vec in PRROC began in Q3 2022 and is ongoing, with interim results expected in January 2026[189]. - The company co-sponsors a Phase 1b/2 clinical trial of Olvi-Vec in recurrent SCLC in China, with interim results expected throughout 2026[185]. - Clinical trial outcomes are uncertain, and previous positive results do not guarantee future success in later-stage trials[209]. - Variability in safety and efficacy results can occur due to factors such as trial design, patient population differences, and adherence to protocols[211]. - The design of clinical trials can significantly influence the likelihood of obtaining marketing approval, and flaws may not be apparent until advanced stages[209]. - Fast track designation does not guarantee faster approval or increased likelihood of marketing approval for Olvi-Vec or future candidates[214]. - The company lacks experience in successfully completing registration-stage clinical trials, which may hinder the execution of trials necessary for marketing approval[209]. - Regulatory agencies may interpret data differently, impacting the approvability and commercialization of Olvi-Vec and other product candidates[213]. Manufacturing and Commercialization - The company has established a cGMP manufacturing facility in San Diego, California, to support clinical trials and the potential commercial launch of Olvi-Vec[20]. - The company plans to build commercialization capabilities as product candidates advance through clinical development[72]. - The company has entered into a License Agreement with Newsoara BioPharma for the commercialization of Olvi-Vec in China, including mainland China, Taiwan, Hong Kong, and Macau[19]. - The Newsoara License Agreement has generated $11.0 million in payments to date, with potential milestone payments up to $160.5 million[65]. - Newsoara is responsible for funding the costs of the VIRO-25 clinical trial in the United States and China[66]. - The company has a portfolio of oncolytic VACV constructs in early-to-late stages of discovery and preclinical development, which may never advance to clinical-stage development[186]. - The company faces significant uncertainty regarding coverage and reimbursement from third-party payors, which may limit product sales[137]. - Third-party payors are increasingly challenging drug pricing and may require expensive pharmacoeconomic studies to demonstrate cost-effectiveness[140]. - The U.S. government has implemented measures such as the Medicare Drug Price Negotiation Program, which may significantly reduce reimbursement rates for certain products[141]. - The company must navigate varying pricing and reimbursement schemes across EU member states, which can create barriers to market entry[143]. - Legislative and regulatory proposals aimed at healthcare reform may impact the company's ability to sell products profitably[145]. Financial Performance and Risks - The company reported net losses of $32.1 million and $29.9 million for the years ended December 31, 2025, and 2024, respectively, with an accumulated deficit of $283.5 million as of December 31, 2025[166]. - The company has never generated any revenue from commercially approved product sales and anticipates incurring significant and increasing operating losses for the foreseeable future[166]. - The company expects that it will be several years, if ever, before it has a commercialized product[168]. - The company requires substantial additional financing to advance the development of Olvi-Vec and future product candidates, which may not be available on acceptable terms[169]. - Existing cash, cash equivalents, and marketable securities are expected to fund planned operations into the first quarter of 2027, but this estimate is based on assumptions that may prove incorrect[172]. - The company has never generated any revenue from commercially approved product sales and does not anticipate doing so until after receiving marketing approval for a product candidate[174]. - The report from the independent registered public accounting firm included a "going concern" explanatory paragraph, indicating substantial doubt about the company's ability to continue as a going concern[180]. - Failure to obtain capital when needed may force the company to delay or terminate product development, adversely affecting its business and financial condition[179]. Regulatory Environment - The FDA requires substantial time and financial resources for the testing and approval process of biological products, which can take many years[93]. - Clinical trials must be conducted under Good Clinical Practice (GCP) regulations, ensuring the safety and rights of trial participants[98]. - The FDA may impose sanctions or discontinue clinical trials if they do not comply with requirements or present unacceptable risks[105]. - Manufacturers must comply with cGMP regulations, ensuring quality control and documentation, and are subject to inspections by government authorities[106]. - The FDA reviews a BLA within 60 days to determine if it is substantially complete before accepting it for filing[112]. - The FDA may issue an approval letter or a complete response letter based on the BLA and inspection results, outlining any deficiencies[115]. - The FDA may require post-marketing clinical trials to further assess a product's safety and effectiveness after approval[117]. - Fast Track and Breakthrough Therapy designations expedite the development and review process for products addressing serious conditions[120]. - Accelerated approval may be granted if a product candidate shows effects on a surrogate endpoint likely to predict clinical benefit, with confirmatory studies required[123]. - The company is subject to ongoing annual program user fee requirements for approved products, excluding certain orphan products[125]. - Post-approval requirements include reporting cGMP deviations and adverse effects, as well as submitting periodic reports to the FDA[131]. - Non-compliance with healthcare laws may result in severe penalties, including fines and exclusion from government-funded healthcare programs[136]. - The company is required to register establishments with the FDA and is subject to inspections to ensure compliance with regulations[128]. - The company faces risks related to government regulation, including potential impacts from healthcare reform measures and changes in reimbursement policies[165]. - The company’s operations may be adversely affected by environmental regulations and the handling of hazardous substances[159]. Human Capital and Corporate Structure - The company’s human capital strategy includes a total compensation package consisting of base salary, cash target bonus, and equity compensation, with 25 full-time employees and 1 part-time employee as of December 31, 2025[161]. - The company completed its initial public offering (IPO) in January 2023, and its common stock is listed on the Nasdaq Capital Market under the symbol "GNLX"[162]. - The company is classified as an "emerging growth company" and will retain this status until certain financial thresholds are met, including total annual gross revenue of at least $1.235 billion[163]. - The company is subject to numerous data privacy and security obligations, including compliance with the Federal Trade Commission Act and the California Consumer Privacy Act[153]. - The company relies on trade secrets and know-how, along with confidentiality agreements, to protect its proprietary information and maintain a competitive position[79].

Financial Performance - Scholastic reported Q3 fiscal 2026 revenues of $329.1 million, a decrease of 2% from $335.4 million in Q3 fiscal 2025[10] - The operating loss for Q3 fiscal 2026 was $26.9 million, compared to a loss of $23.9 million in the same quarter last year, reflecting a 13% increase[12] - Adjusted EBITDA for Q3 fiscal 2026 was $0.0 million, down from $6.0 million in Q3 fiscal 2025, marking a 100% decline[12] - Year-to-date revenues for fiscal 2026 were $1,105.8 million, a decline of 1% from $1,117.2 million in the prior year[26] - Revenues for the three months ended February 28, 2026, were $329.1 million, a decrease of 1% from $335.4 million in the same period last year[38] - Operating income for the three months ended February 28, 2026, was a loss of $26.9 million, compared to a loss of $23.9 million in the prior year[38] - Net income for the three months ended February 28, 2026, was $62.5 million, a significant improvement from a net loss of $3.6 million in the same period last year[38] - Basic earnings per share for the three months ended February 28, 2026, were $2.61, compared to a loss of $0.13 per share in the prior year[38] - Total revenues for the nine months ended February 28, 2026, increased to $1,105.8 million, up 2% from $1,117.2 million in the previous year[38] Segment Performance - The Education segment's revenues decreased by 2% to $56.1 million, with an operating loss improving to $5.2 million from $6.9 million year-over-year[14] - The Entertainment segment saw a revenue increase of 25% to $16.0 million, with an operating loss improving to $3.5 million[15] - The Children's Book Publishing and Distribution segment reported a 3% decline in revenues for the three months ended February 28, 2026, totaling $197.6 million[40] - Book Fairs revenues increased by 2% to $113.3 million for the three months ended February 28, 2026, compared to $110.7 million in the prior year[40] - Education Solutions revenues decreased by 2% to $56.1 million for the three months ended February 28, 2026, down from $57.2 million[40] - The Entertainment segment saw a 25% increase in revenues to $16.0 million for the three months ended February 28, 2026, compared to $12.8 million in the previous year[40] - International revenues for the three months ended February 28, 2026, decreased by 1% to $58.7 million, down from $59.3 million[40] Cash Flow and Financial Position - Scholastic's free cash flow for fiscal 2026 is forecasted to exceed $430 million, driven by proceeds from sale-leaseback transactions[7] - Net cash used in operating activities was $30.5 million, compared to $12.0 million in the prior year, primarily due to higher tax payments[21] - Cash and cash equivalents increased to $104.6 million as of February 28, 2026, up from $94.7 million a year earlier, representing a growth of 6.8%[42] - Net cash provided by operating activities was $(30.5) million for the three months ended February 28, 2026, compared to $(12.0) million for the same period last year, indicating a decline in operational cash flow[42] - Free cash flow for the three months ended February 28, 2026, was $407.0 million, a significant increase from $(30.7) million in the prior year, reflecting improved cash generation[42] - Total stockholders' equity decreased to $871.9 million as of February 28, 2026, down from $941.3 million a year earlier, reflecting a decline of 7.4%[42] - The company’s accounts receivable decreased to $248.3 million as of February 28, 2026, from $255.9 million a year earlier, showing a reduction of 3.0%[42] - The company’s deferred revenue increased to $213.7 million as of February 28, 2026, compared to $205.2 million a year earlier, reflecting a growth of 4.1%[42] Earnings and Taxation - For the three months ended February 28, 2026, the total earnings before income taxes reported was $91.8 million, compared to a loss of $28.4 million for the same period in 2025, indicating a significant improvement[54] - Adjusted EBITDA for the three months ended February 28, 2026, was $0.0 million, a decrease from $6.0 million in the same period of the previous year[54] - For the nine months ended February 28, 2026, total earnings before income taxes reported was $70.7 million, up from a loss of $50.2 million for the same period in 2025[54] - The adjusted EBITDA for the nine months ended February 28, 2026, was $66.8 million, compared to $54.2 million for the same period in 2025, reflecting a year-over-year increase[54] - The Children's Book Publishing and Distribution segment reported earnings before income taxes of $82.4 million for the nine months ended February 28, 2026, compared to $73.0 million in the same period of 2025[54] - The Education Solutions segment experienced a loss before income taxes of $31.1 million for the nine months ended February 28, 2026, an improvement from a loss of $24.4 million in the same period of 2025[54] - The Entertainment segment reported a loss before income taxes of $17.9 million for the nine months ended February 28, 2026, compared to a loss of $11.4 million for the same period in 2025[54] - The International segment showed a profit of $1.9 million for the nine months ended February 28, 2026, a turnaround from a loss of $6.0 million in the same period of 2025[54] - One-time items before income taxes for the nine months ended February 28, 2026, totaled a negative impact of $93.2 million, primarily due to a $104.3 million loss in the Overhead segment[54] - The company recorded a $6.7 million impact from sale-leaseback transactions in Overhead for the three and nine months ended February 28, 2026[55] Shareholder Actions - The company has authorized a new $300 million share repurchase program, including a $200 million modified Dutch auction tender offer[24]

Financial Performance - The company has incurred net losses of $1.9 million and $15.8 million for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of $398.6 million as of December 31, 2025[131]. - The company raised approximately $14.5 million in net proceeds during the year ended December 31, 2025, which includes proceeds from an equity offering and warrant exercises[138]. - As of December 31, 2025, the company had cash and cash equivalents of $17.3 million, which is expected to fund operations for at least twelve months[137]. - The company anticipates continued significant operating losses and negative cash flows as it develops its product candidates[139]. - The company has recognized approximately $2.1 million in savings during the year ended December 31, 2025, through negotiations of aged payables and cost reductions[138]. Product Development and Regulatory Challenges - The company does not expect to generate any revenues from product sales in the foreseeable future, as it currently has no products approved for commercial sale[131]. - The company may face challenges in obtaining regulatory approvals and establishing a commercial organization for its product candidates[147]. - The development and commercialization of the company's CAR T product candidates face significant challenges, including regulatory approval and establishing market demand[166]. - Delays in clinical trials could increase costs and hinder the ability to pursue regulatory approval for product candidates[172]. - The company must obtain FDA approval for any proposed product brand names, and delays in this process may adversely impact commercialization efforts[204]. Market and Competitive Landscape - Market acceptance of product candidates is crucial for revenue generation, which depends on factors such as efficacy, safety, and third-party reimbursement[215]. - The company faces significant uncertainty regarding third-party coverage and reimbursement for newly approved drugs, which is essential for commercial success[217]. - Competitors may develop alternative formulations that do not infringe on in-licensed patent rights, significantly harming the commercial opportunity for the company's product candidates[210]. - Generic therapies are typically sold at lower prices and may pose a significant competitive threat to the company's product candidates once patents expire[211]. Intellectual Property and Licensing - The company relies on patent protection for its technology, and uncertainties in the patent application process could impair commercialization efforts[279]. - The company may need to license intellectual property from third parties, which may not be available on commercially reasonable terms, impacting product development[255]. - Disputes with licensors regarding intellectual property could adversely affect the company's ability to develop and commercialize product candidates[306]. - The complexity of licensing agreements may lead to lengthy and expensive disputes, potentially impacting the company's financial condition and operations[307]. Operational Risks - The company relies on contract manufacturers for production, and any failure to meet regulatory compliance or production volumes could result in delays and lost revenues[191]. - The company is dependent on institutions like COH, Nationwide, and UAB for research and development, which limits control over the nature and timing of research activities[240]. - The company faces potential disruptions in the supply chain for raw materials, which could delay clinical trials and regulatory approvals[242]. - Compliance with Good Manufacturing Practices (cGMP) is essential, and failure to comply could result in significant sanctions, including clinical holds and fines[244]. Regulatory Environment - The FDA and other regulatory agencies can delay or deny approval of product candidates due to various reasons, including safety and efficacy concerns, which may lead to significant delays in commercialization[184]. - Legislative changes, such as the ACA, have increased Medicaid rebates from 15.1% to 23.1%, affecting the company's ability to profitably sell products[258]. - The Inflation Reduction Act of 2022 introduces a drug price negotiation program, requiring manufacturers to charge a negotiated "maximum fair price" for certain drugs or face penalties, which could adversely affect profitability[261]. - Changes in U.S. government policy and regulation could adversely affect the company's business and financial condition, impacting drug approval processes and reimbursement levels[231]. Human Resources and Management - The company faces challenges in attracting and retaining key personnel due to intense competition in the biotechnology and pharmaceutical sectors, which could impede its business objectives[324]. - Employee misconduct or noncompliance with regulatory standards could have a material adverse effect on the company's business and may result in significant fines or sanctions[325]. - The dual roles of directors serving both the company and Fortress could create conflicts of interest that require careful monitoring[313]. External Factors - Economic and geopolitical conditions can adversely affect the company's cash flows, results of operations, and ability to access capital[322]. - Trade policies and geopolitical disputes, particularly between the U.S. and China, may lead to increased tariffs and restrictions that could adversely affect the company's operations and financial condition[323]. - Disruptions from natural or man-made disasters could lead to increased costs, delays in research and development, and reduced revenue opportunities, adversely affecting the company's financial condition[328].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40710 Tigo Energy, Inc. (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of incorporation or organ ...

Financial Performance - Net revenue for the year ended December 31, 2025, was $103.5 million, representing an increase of $49.5 million or 91.7% compared to $54.0 million in 2024[352] - Gross profit for 2025 was $44.4 million, a significant improvement of $48.5 million compared to a loss of $4.2 million in 2024, resulting in a gross margin of 42.8%[352] - Total net revenue for the year ended December 31, 2025, was $103.5 million, representing a 91.7% increase compared to $54.0 million in 2024[358] - EMEA region net revenue increased by $36.9 million or 113.2%, driven by higher demand for MLPE products in several countries[363] - Demand for products increased in 2025, contributing to a revenue growth of 91.7% compared to 2024, driven by recovery in major markets[346] Product Line Performance - The MLPE product line contributed $42.1 million to net revenue, reflecting an increase of 87.2% year-over-year, driven by market recovery and acceptance[355] - The GO ESS product line saw a revenue increase of $6.2 million or 178.6% for 2025, attributed to heightened solar repowering activities[355] Expenses and Costs - Research and development expenses decreased by $0.6 million or 6.2% to $9.2 million, representing 8.9% of net revenue in 2025[368] - Sales and marketing expenses increased by $0.5 million or 3.0% to $17.4 million, accounting for 16.8% of net revenue[372] - General and administrative expenses rose by $1.1 million or 5.3% to $22.2 million, representing 21.4% of net revenue[375] - The company experienced a 1.7% increase in cost of revenue, totaling $59.2 million for 2025 compared to $58.2 million in 2024[362] - The gross margin improved to 42.8% in 2025, up from a gross margin of (7.7)% in 2024, reflecting better product mix and reduced inventory expenses[365] Cash Flow and Financial Position - The company generated net cash provided by operating activities of $10.3 million for the year ended December 31, 2025, compared to a net cash used of $12.4 million in 2024[393] - Net cash provided by investing activities was $22.6 million for the year ended December 31, 2025, primarily from the sale and maturities of marketable securities[395] - As of December 31, 2025, the company had cash and cash equivalents of $7.7 million and total working capital of $19.2 million[387] - The company repaid $51.3 million in cash to extinguish its Convertible Promissory Notes, resulting in no outstanding debt obligations as of December 31, 2025[391] Legal and Regulatory Matters - The One Big Beautiful Bill Act of 2025 introduces changes to clean energy tax credits, potentially impacting the company's financial condition and competitiveness[341] - The current provision for income taxes involves estimates, assumptions, and judgments based on current tax laws and potential outcomes of future tax audits[418] - Reserves have been established to address potential exposures related to tax positions that could be challenged by tax authorities[418] - Changes in tax law or interpretation could significantly impact the amounts provided for income taxes in the consolidated financial statements[418] Other Financial Transactions - The company extinguished its Convertible Promissory Notes on December 17, 2025, incurring a loss of $1.1 million[334] - A patent sale agreement was executed on December 16, 2025, with total expected consideration between $15.0 million and $18.0 million, of which $15.0 million was received at the initial closing[336] - A patent purchase agreement was entered into on December 16, 2025, with total consideration potentially reaching between $15.0 million and $18.0 million[390] - The company recorded total lease obligations of $2.7 million as of December 31, 2025, related to non-cancelable operating leases[392] Impairment and Liabilities - The product warranty liability increased to $9.3 million for the year ended December 31, 2025, compared to $5.8 million in 2024[406] - The company assessed goodwill for impairment, with fair value exceeding carrying value by 257.9% during the annual test conducted in the fourth quarter of 2025[410] - The net deferred tax asset balance was $0.3 million, net of a valuation allowance of $37.1 million as of December 31, 2025[416] - Total other expenses, net, showed a significant decline of $13.9 million, resulting in total other expenses of $(3.2) million for 2025[378]

Financial Performance - Fourth quarter 2025 net revenues were $25.1 million, a decrease from $26.2 million in the same period last year, primarily due to a $3.5 million decrease in deferred revenues[11]. - Full year 2025 net revenues were $81.2 million, down from $84.5 million, mainly due to a $15.5 million decrease in recognition of deferred revenues related to the ARK franchise[16]. - Total revenues for the year ended December 31, 2025, were $81,225,622, a decrease of 3.0% from $84,467,047 in 2024[34]. - Gross profit for 2025 was $22,430,675, down 25.7% from $30,230,705 in 2024[34]. - The company reported a gross profit margin of 27.6% for 2025, down from 35.7% in 2024[34]. - Net loss for the fourth quarter was $(0.9) million, compared to net income of $1.1 million in the same period last year, primarily due to a decrease in gross profit[13]. - Full year net loss was $(27.2) million, compared to net income of $1.8 million in the previous year, largely due to a non-cash tax expense of $10.1 million[18]. - The net loss attributable to Snail, Inc. for 2025 was $27,235,125, compared to a net income of $1,831,940 in 2024[34]. - Net income for 2025 was a loss of $27,237,732 compared to a profit of $1,827,075 in 2024[37]. Sales and Bookings - Total units sold increased to 1.5 million, up 15.4% from 1.3 million units in the same period last year, driven by a 0.2 million unit increase in ASA sales[12]. - Bookings for the fourth quarter increased to $20.8 million, up 22.4% from $17.0 million in the same period last year[14]. - Full year 2025 bookings rose 16.2% to $87.8 million compared to $75.7 million in the previous year, driven by increased ASA sales[19]. Cash and Assets - As of December 31, 2025, unrestricted cash was $8.6 million, an increase from $7.3 million as of December 31, 2024[15]. - Cash and cash equivalents as of December 31, 2025, were $8,568,164, an increase from $7,303,944 in 2024[30]. - Total cash and cash equivalents at the end of 2025 increased to $10,503,164 from $8,238,944 at the end of 2024[38]. - Total current liabilities rose to $49,806,622 in 2025, up from $36,181,080 in 2024, marking an increase of 37.6%[30]. - Total assets decreased to $59,307,138 in 2025 from $62,193,364 in 2024, a decline of 4.5%[30]. - The total stockholders' equity (deficit) as of December 31, 2025, was $(21,879,053), compared to $4,169,162 in 2024[32]. Expenses and Investments - Operating expenses increased to $39,693,983 in 2025, compared to $26,341,615 in 2024, reflecting a rise of 50.9%[34]. - Research and development expenses for 2025 were $14,580,668, an increase of 25.5% from $11,647,293 in 2024[34]. - The company invested $4,093,027 in software licenses and $290,000 in software acquisition during 2025[37]. Other Financial Metrics - Cash flows from operating activities resulted in a net cash used of $1,153,056 in 2025, an improvement from $1,565,124 in 2024[37]. - Financing activities provided a net cash inflow of $8,705,592 in 2025, compared to a net cash outflow of $6,485,621 in 2024[37]. - The company reported a deferred tax asset of $10,817,741 in 2025, a significant increase from a deferred tax liability of $569,601 in 2024[37]. - The company experienced a loss of $719,925 on the change in fair value of warrant liabilities in 2025, contrasting with a gain of $1,332,815 in 2024[37]. - Cash paid for interest in 2025 was $617,246, up from $467,188 in 2024[38]. - The company recorded an impairment of film assets amounting to $868,722 in 2025[37]. - The effect of foreign currency translation on cash and cash equivalents resulted in a loss of $30,634 in 2025[38]. Future Outlook - The ARK franchise is expected to maintain momentum with a robust content roadmap through 2027, including multiple new titles and expansions[7]. - The company is investing in AAA game development, with titles like For The Stars and Nine Yin Sutra: Immortal expected to deliver substantial upside and attractive profit margins[8].

Revenue Performance - Revenue for the quarter ended December 31, 2025, was RMB 284,843 million (US$ 40,732 million), an increase of 2% year-over-year; on a like-for-like basis, revenue would have grown by 9%[7] - Revenue for the quarter ended December 31, 2025, was RMB284,843 million (US$40,732 million), a 2% increase year-over-year[28] - Alibaba China E-commerce Group revenue increased by 6% year-over-year to RMB159,347 million (US$22,786 million)[28] - Quick commerce revenue surged by 56% year-over-year to RMB20,842 million (US$2,980 million), driven by the rollout of "Taobao Instant Commerce"[33] - International commerce retail revenue increased by 3% year-over-year to RMB32,351 million (US$4,626 million), driven by AliExpress and other international businesses[36] - For the nine months ended December 31, 2025, Alibaba's consolidated revenue increased to RMB 780,290 million, representing a 3% year-over-year growth[104] - The Alibaba China E-commerce Group reported a total revenue of RMB 431,997 million for the nine months ended December 31, 2025, reflecting a 10% year-over-year increase[104] - The Cloud Intelligence Group achieved a revenue of RMB 116,506 million for the nine months ended December 31, 2025, marking a 33% year-over-year increase[104] Profitability Metrics - Income from operations decreased by 74% year-over-year to RMB 10,645 million (US$ 1,522 million), primarily due to a decrease in adjusted EBITA[7] - Adjusted EBITA decreased by 57% year-over-year to RMB 23,397 million (US$ 3,346 million), attributed to investments in quick commerce and technology[7] - Net income attributable to ordinary shareholders was RMB 16,322 million (US$ 2,334 million), a decrease of 67% year-over-year[7] - Adjusted EBITA for Alibaba China E-commerce Group decreased by 43% to RMB34,613 million (US$4,949 million) due to investments in quick commerce and technology[35] - Adjusted EBITDA decreased 45% year-over-year to RMB34,057 million (US$4,870 million) for the quarter ended December 31, 2025, compared to RMB62,054 million in the same quarter of 2024[56] - Net income for the quarter ended December 31, 2025, was RMB15,631 million (US$2,235 million), a decrease from RMB46,434 million in the same quarter of 2024[64] - Non-GAAP net income for the three months ended December 31, 2025, was RMB 16,710 million, down from RMB 51,066 million in Q4 2024, a decline of approximately 67%[98] - Adjusted EBITA for the Alibaba China E-commerce Group fell to RMB 83,499 million for the nine months ended December 31, 2025, a decline of 46% year-over-year[105] - The total adjusted EBITA for the company decreased to RMB 71,314 million for the nine months ended December 31, 2025, a 49% decline year-over-year[105] Expenses and Costs - Total costs and expenses for the quarter were RMB275,659 million (US$39,419 million), reflecting an increase in sales and marketing expenses[43] - Cost of revenue was RMB169,534 million (US$24,243 million), or 59.5% of revenue, up from 58.0% in the same quarter of 2024[44] - Sales and marketing expenses for the quarter ended December 31, 2025, were RMB71,934 million (US$10,286 million), representing 25.3% of revenue, up from 15.2% in the same quarter of 2024[46] - General and administrative expenses decreased to RMB8,355 million (US$1,195 million), or 2.9% of revenue, down from 3.9% in the same quarter of 2024[47] - Total share-based compensation expense increased by 26% to RMB4,859 million (US$695 million) in the quarter ended December 31, 2025, compared to RMB3,865 million in the same quarter of 2024[48] Cash Flow and Liquidity - Free cash flow for the quarter ended December 31, 2025, was RMB11,346 million (US$1,622 million), a decrease of 71% compared to RMB39,020 million in the same quarter of 2024[71] - Net cash provided by operating activities for the three months ended December 31, 2025, was RMB 36,032 million, down from RMB 70,915 million in the same period of 2024, a decline of about 49%[96] - Net cash used in investing activities significantly decreased from RMB 111,003 million in Q4 2024 to RMB 25,716 million in Q4 2025, a reduction of approximately 77%[96] - Cash and cash equivalents, short-term investments, and other treasury investments totaled RMB560,175 million (US$80,104 million) as of December 31, 2025, down from RMB597,132 million as of March 31, 2025[70] - Cash and cash equivalents at the end of the period decreased from RMB 205,966 million as of December 31, 2024, to RMB 170,519 million as of December 31, 2025, a reduction of about 17%[96] Market Position and Strategic Initiatives - The Cloud Intelligence Group's revenue grew by 36% year-over-year to RMB 43,284 million (US$ 6,190 million), driven by public cloud revenue growth and AI-related products[15] - The number of 88VIP members surpassed 59 million, reflecting a double-digit year-over-year increase[12] - The quick commerce business improved unit economics and increased average order value month-over-month, supported by logistics efficiency enhancements[9] - Qwen app reached approximately 300 million monthly active users, with significant user engagement following its upgrade on January 15, 2026[25] - Alibaba Cloud maintained a 43% market share in China's financial cloud market, leading for six consecutive years[17] - T-Head's proprietary GPU is now in production, enhancing Alibaba's AI service capabilities and contributing to cloud infrastructure supply[22] - The company aims to enhance its market position through strategic investments and acquisitions, although specific future projections were not detailed[80] - The company undertook a strategic combination of Taobao and Tmall Group, Ele.me, and Fliggy into the Alibaba China E-commerce Group to enhance user experience[104] Impairments and Liabilities - Impairment of goodwill increased by 54% to RMB9,515 million (US$1,361 million) in the quarter ended December 31, 2025, compared to RMB6,171 million in the same quarter of 2024[54] - Total liabilities decreased from RMB 772,371 million as of December 31, 2024, to RMB 714,121 million as of March 31, 2025, representing a reduction of approximately 7.5%[95] - Current liabilities as of December 31, 2025, were RMB 459,811 million (US$ 65,752 million), compared to RMB 435,346 million as of March 31, 2025[94] - The company reported a significant increase in deferred tax liabilities from RMB 46,232 million as of December 31, 2024, to RMB 48,454 million as of March 31, 2025, an increase of about 4.8%[95]